S Mas1,2,3, P Gassó1,2,3, N Rodríguez4, B Cabrera2,5, G Mezquida3,6,7, A Lobo8, A González-Pinto2,9,10,11, M Parellada12, I Corripio2,13,14,15, E Vieta2,3,16,17, J Castro-Fornieles2,3,17,18, J Bobes2,19,20, J Usall21,22, J Saiz-Ruiz23, F Contreras2,3,24,25, E Parellada2,3,17,26, M Bernardo2,3,17,26. 1. Pharmacology Unit, Department of Clinical Foundations, University of Barcelona, Barcelona, Spain. 2. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain. 3. Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPs), Barcelona, Spain. 4. Fundació Clinic per la Recerca Biomédica (FCRB), Barcelona, Spain. 5. Barcelona Clínic Schizophrenia Unit, Neuroscience Institute Hospital Clínic de Barcelona, Barcelona, Spain. 6. Barcelona Clinic Schizophrenia Unit, Hospital Clinic of Barcelona, Barcelona, Spain. 7. Fundació Clínic per la Recerca Biomèdica (FCRB), Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain. 8. Department of Medicine and Psychiatry, University of Zaragoza, Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain. 9. Department of Psychiatry, Hospital Universitario de Alava, Vitoria, Spain. 10. BIOARABA Health Research Institute, Vitoria, Spain. 11. University of the Basque Country, Vitoria, Spain. 12. Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain. 13. Servicio de Psiquiatría, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 14. Instituto de Investigación Biomédica Sant Pau (IIB-SANT PAU), Barcelona, Spain. 15. Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. 16. Hospital Clínic de Barcelona, Barcelona, Spain. 17. Department of Medicine, University of Barcelona, Barcelona, Spain. 18. Child and Adolescent Psychiatry and Psychology Department, 2017SGR881, Institute Clinic of Neurosciences, Hospital Clinic of Barcelona, Barcelona, Spain. 19. Área de Psiquiatría, Hospital Universitario Central de Asturias (HUCA), Universidad de Oviedo, Asturias, Spain. 20. Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Asturias, Spain. 21. Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain. 22. Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain. 23. Hospital Ramon y Cajal, Universidad de Alcala, IRYCIS, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain. 24. Psychiatric Service, Bellvitge University Hospital, Hospitalet del Llobregat, Spain. 25. University of Barcelona, Barcelona, Spain. 26. Barcelona Clínic Schizophrenia Unit, Neuroscience Institute, Hospital Clínic of Barcelona, Barcelona, Spain.
Abstract
AIMS: Here, we present a clustering strategy to identify phenotypes of antipsychotic (AP) response by using longitudinal data from patients presenting first-episode psychosis (FEP). METHOD: One hundred and ninety FEP with complete data were selected from the PEPs project. The efficacy was assessed using total PANSS, and adverse effects using total UKU, during one-year follow-up. We used the Klm3D method to cluster longitudinal data. RESULTS: We identified four clusters: cluster A, drug not toxic and beneficial; cluster B, drug beneficial but toxic; cluster C, drug neither toxic nor beneficial; and cluster D, drug toxic and not beneficial. These groups significantly differ in baseline demographics, clinical, and neuropsychological characteristics (PAS, total PANSS, DUP, insight, pIQ, age of onset, cocaine use and family history of mental illness). CONCLUSIONS: The results presented here allow the identification of phenotypes of AP response that differ in well-known simple and classic clinical variables opening the door to clinical prediction and application of personalized medicine.
AIMS: Here, we present a clustering strategy to identify phenotypes of antipsychotic (AP) response by using longitudinal data from patients presenting first-episode psychosis (FEP). METHOD: One hundred and ninety FEP with complete data were selected from the PEPs project. The efficacy was assessed using total PANSS, and adverse effects using total UKU, during one-year follow-up. We used the Klm3D method to cluster longitudinal data. RESULTS: We identified four clusters: cluster A, drug not toxic and beneficial; cluster B, drug beneficial but toxic; cluster C, drug neither toxic nor beneficial; and cluster D, drug toxic and not beneficial. These groups significantly differ in baseline demographics, clinical, and neuropsychological characteristics (PAS, total PANSS, DUP, insight, pIQ, age of onset, cocaine use and family history of mental illness). CONCLUSIONS: The results presented here allow the identification of phenotypes of AP response that differ in well-known simple and classic clinical variables opening the door to clinical prediction and application of personalized medicine.
Authors: Shaunagh O'Sullivan; Lianne Schmaal; Simon D'Alfonso; Yara Jo Toenders; Lee Valentine; Carla McEnery; Sarah Bendall; Barnaby Nelson; John F Gleeson; Mario Alvarez-Jimenez Journal: JMIR Ment Health Date: 2022-04-07